ISRCTN32862552 https://doi.org/10.1186/ISRCTN32862552

Tapering off Inhaled Corticosteroids in Asthma patients after Reduction of Allergens

Submission date	Recruitment status	[_] Prospectively registered
19/12/2005	No longer recruiting	[_] Protocol
Registration date	**Overall study status**	[_] Statistical analysis plan
19/12/2005	Completed	[X] Results
Last Edited	**Condition category**	[_] Individual participant data
25/08/2009	Respiratory	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof C.P. Schayck, van

Contact details
University Maastricht
Care and Public Health Research Institute - CAPHRI
Department of General Practice
P.O. Box 616
Maastricht
Netherlands
6200 MD
+31 (0)43 3882446
onno.vanschayck@hag.unimaas.nl

Additional identifiers

Protocol serial number
NTR370

Study information

Scientific Title

Acronym
TICARA

Study objectives
Allergen avoidance allows tapering off inhaled corticosteroids (ICS) in house dust mite allergic asthma patients

Ethics approval required
Old ethics approval format

Ethics approval(s)
Received from local medical ethics committee

Study design
Multicentre randomised double blind placebo controlled parallel group trial

Primary study design
Interventional

Study type(s)
Other

Health condition(s) or problem(s) studied
Asthma, Allergy

Interventions
All patients have been trained to use a self-management plan to adjust the dose of inhaled corticosteroids to symptoms and peak expiratory flow value.
After a run-in period of 3 months the intervention period with placebo controlled allergen avoidance started.
The participants in the intervention group received house dust mite impermeable covers for mattress, pillow and bedding.
The control group received placebo, house dust mite permeable, covers.

Intervention Type
Other

Phase
Not Specified

Primary outcome(s)
Use of inhaled corticosteroids

Key secondary outcome(s))
1. Asthma control
2. Symptoms (dyspnoea, wheezing, coughing)
3. Peak flow parameters (morning peak flow, peak flow variability)

Completion date
01/12/2004

Eligibility

Key inclusion criteria
1. Age 16-60 years
2. Treatment for asthma by the GP
3. Use of inhaled corticosteroids
4. Allergy for house dust mite allergens

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Adult

Sex
All

Key exclusion criteria
1. Serious diseases other than asthma with a low survival rate
2. Other diseases, which influence bronchial symptoms and/or lung function
3. Exacerbation within one month before the start of the study
4. The use of oral steroids or inhaled cromoglycates
5. Use of house dust mite impermeable mattress/bedding covers
6. Allergy to cats or dogs while keeping these pets

Date of first enrolment
01/01/1999

Date of final enrolment
01/12/2004

Locations

Countries of recruitment
Netherlands

Study participating centre
University Maastricht
Maastricht
Netherlands
6200 MD

Sponsor information

Organisation
Care and Public Health Research Institute (CAPHRI), University Maastricht (Netherlands)

ROR
https://ror.org/02jz4aj89

Funder(s)

Funder type
Research organisation

Funder Name
Netherlands Organisation for Health Research and Development (ZonMw) (Netherlands)

Alternative Name(s)
Netherlands Organisation for Health Research and Development

Funding Body Type
Private sector organisation

Funding Body Subtype
Other non-profit organizations

Location
Netherlands

Funder Name
Netherlands Asthma Foundation (Netherlands)

Funder Name
Boehringer Ingelheim BV (Netherlands)

Funder Name
AstraZeneca BV (Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/04/2006		Yes	No